STRONG EVIDENCE
15 level-I · 15 level-II · 4 level-IV · 1 level-III · 1 level-VII
Research base (design-resolved): 15 systematic review/meta-analysis, 15 randomized trials, 5 observational/descriptive.
low · 131 mentions
Most discussed for: oral_medication, biologic
What the research says
Baricitinib demonstrated superior therapeutic effects compared to placebo.
Liao et al. (2025), PLoS ONE. doi:10.1371/journal.pone.0319400 · verifiedBaricitinib has been recently approved in Europe and Japan for the treatment of atopic dermatitis in adult patients.
Morelli et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1393799 · verifiedBaricitinib treatment resulted in a significant increase in EASI-75 response rate compared to placebo.
Zheng et al. (2024), Frontiers in Immunology. doi:10.3389/fimmu.2024.1367099 · verifiedBaricitinib is effective in the therapy of patients with moderate-to-severe atopic dermatitis.
Makowska et al. (2023), International Journal of Molecular Sciences. doi:10.3390/ijms24010781 · verifiedBaricitinib is effective in achieving EASI-75 response in AD patients. (n=4367)
Tampa et al. (2023), Journal of Personalized Medicine. doi:10.3390/jpm13030384 · verifiedBaricitinib has been effective in reducing the severity of atopic dermatitis. (n=4)
Sadowsky et al. (2023), Journal of Clinical Medicine. doi:10.3390/jcm12175534 · verifiedBaricitinib significantly improves clinical pictures in AD patients.
Lugović‐Mihić et al. (2023), Life. doi:10.3390/life13061419 · verifiedWhat the community reports
Experience reports, not evidence. Volumes from 1.1M triaged posts.
- oral_medication
- biologic
Safety and side effects
Some reported safety concerns include headaches, upper respiratory tract infections, and abdominal pain, among others.
For infants and children
Baricitinib is approved for patients aged 2 years and older in Europe.
Studied protocols
As reported in the papers, not recommendations.
dose: 4 mg and 2 mg; frequency: once daily; route: oral
Howell et al. (2019), Frontiers in Immunologyroute: oral
Szilveszter et al. (2019), Frontiers in Immunologydose: 4 mg, 2 mg; frequency: once daily; route: oral; duration: 16 weeks
Szalus et al. (2020), Microorganismsdose: 1 mg, 2 mg, and 4 mg; frequency: once daily; route: oral; duration: 16 weeks
Makowska et al. (2023), International Journal of Molecular Sciencesroute: oral; duration: 16 weeks
Caffarelli et al. (2023), Frontiers in Medicinedose: 2 mg; frequency: twice daily; route: oral; duration: 16 weeks
Ali et al. (2022), Frontiers in MedicineDrawn from 36 papers · generated 2026-06-11T12:41:00.413121+00:00 · phrasing by gpt-4o-mini, every number computed from the database and every citation machine-verified.